
Jon E. Angell
Examiner (ID: 6922)
| Most Active Art Unit | 1635 |
| Art Unit(s) | 1637, 1674, 1635 |
| Total Applications | 1428 |
| Issued Applications | 719 |
| Pending Applications | 199 |
| Abandoned Applications | 530 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17037098
[patent_doc_number] => 20210254056
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS
[patent_app_type] => utility
[patent_app_number] => 16/610899
[patent_app_country] => US
[patent_app_date] => 2018-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 542745
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16610899
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/610899 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | May 3, 2018 | Abandoned |
Array
(
[id] => 16105555
[patent_doc_number] => 10695362
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-06-30
[patent_title] => Stabilization method of functional nucleic acid
[patent_app_type] => utility
[patent_app_number] => 15/959809
[patent_app_country] => US
[patent_app_date] => 2018-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 29
[patent_no_of_words] => 20761
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 144
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15959809
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/959809 | Stabilization method of functional nucleic acid | Apr 22, 2018 | Issued |
Array
(
[id] => 15451211
[patent_doc_number] => 20200038429
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-06
[patent_title] => P-ETHOXY NUCLEIC ACIDS FOR IGF-1R INHIBITION
[patent_app_type] => utility
[patent_app_number] => 16/606377
[patent_app_country] => US
[patent_app_date] => 2018-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19963
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -38
[patent_words_short_claim] => 111
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16606377
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/606377 | P-ETHOXY NUCLEIC ACIDS FOR IGF-1R INHIBITION | Apr 18, 2018 | Abandoned |
Array
(
[id] => 15438327
[patent_doc_number] => 20200033347
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-30
[patent_title] => Biomarkers And Targets For Proliferative Diseases
[patent_app_type] => utility
[patent_app_number] => 16/604444
[patent_app_country] => US
[patent_app_date] => 2018-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43645
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604444
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/604444 | Biomarkers And Targets For Proliferative Diseases | Apr 17, 2018 | Abandoned |
Array
(
[id] => 13372479
[patent_doc_number] => 20180237780
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-23
[patent_title] => UNA OLIGOMERS FOR THERAPEUTICS WITH PROLONGED STABILITY
[patent_app_type] => utility
[patent_app_number] => 15/952680
[patent_app_country] => US
[patent_app_date] => 2018-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22224
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15952680
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/952680 | UNA oligomers for therapeutics with prolonged stability | Apr 12, 2018 | Issued |
Array
(
[id] => 16541311
[patent_doc_number] => 20200407724
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-31
[patent_title] => TARGETED COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 16/603771
[patent_app_country] => US
[patent_app_date] => 2018-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33505
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16603771
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/603771 | Targeted compositions | Apr 9, 2018 | Issued |
Array
(
[id] => 18503623
[patent_doc_number] => 11701413
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-18
[patent_title] => RNA for treatment of autoimmune diseases
[patent_app_type] => utility
[patent_app_number] => 16/500005
[patent_app_country] => US
[patent_app_date] => 2018-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 21
[patent_no_of_words] => 27869
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16500005
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/500005 | RNA for treatment of autoimmune diseases | Apr 9, 2018 | Issued |
Array
(
[id] => 18274822
[patent_doc_number] => 11613756
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-03-28
[patent_title] => Compositions and methods for differential induction of cell death and interferon expression
[patent_app_type] => utility
[patent_app_number] => 16/499991
[patent_app_country] => US
[patent_app_date] => 2018-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 50
[patent_no_of_words] => 14849
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16499991
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/499991 | Compositions and methods for differential induction of cell death and interferon expression | Apr 2, 2018 | Issued |
Array
(
[id] => 18910515
[patent_doc_number] => 11873486
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-16
[patent_title] => Modulating dsRNA editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
[patent_app_type] => utility
[patent_app_number] => 16/497294
[patent_app_country] => US
[patent_app_date] => 2018-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 91
[patent_figures_cnt] => 68
[patent_no_of_words] => 109502
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16497294
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/497294 | Modulating dsRNA editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon | Apr 1, 2018 | Issued |
Array
(
[id] => 16253806
[patent_doc_number] => 20200263180
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-20
[patent_title] => RNA TARGETING OF MUTATIONS VIA SUPPESSOR tRNAs AND DEAMINASES
[patent_app_type] => utility
[patent_app_number] => 16/490494
[patent_app_country] => US
[patent_app_date] => 2018-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24879
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16490494
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/490494 | RNA targeting of mutations via suppressor tRNAs and deaminases | Mar 1, 2018 | Issued |
Array
(
[id] => 13790719
[patent_doc_number] => 20190008898
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-10
[patent_title] => Inhibition of Diacylglycerol Kinase to Augment Adoptive T cell Transfer
[patent_app_type] => utility
[patent_app_number] => 15/908388
[patent_app_country] => US
[patent_app_date] => 2018-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33791
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15908388
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/908388 | Inhibition of Diacylglycerol Kinase to Augment Adoptive T cell Transfer | Feb 27, 2018 | Abandoned |
Array
(
[id] => 17436126
[patent_doc_number] => 11261440
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-01
[patent_title] => Antisense oligonucleic acid
[patent_app_type] => utility
[patent_app_number] => 16/487762
[patent_app_country] => US
[patent_app_date] => 2018-02-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 30
[patent_figures_cnt] => 30
[patent_no_of_words] => 13017
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16487762
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/487762 | Antisense oligonucleic acid | Feb 19, 2018 | Issued |
Array
(
[id] => 13537281
[patent_doc_number] => 20180320187
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-08
[patent_title] => TOXIC RNAi ACTIVE SEED SEQUENCES FOR KILLING CANCER CELLS
[patent_app_type] => utility
[patent_app_number] => 15/900392
[patent_app_country] => US
[patent_app_date] => 2018-02-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58519
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 131
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15900392
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/900392 | Toxic RNAi active seed sequences for killing cancer cells | Feb 19, 2018 | Issued |
Array
(
[id] => 17953679
[patent_doc_number] => 11479773
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-25
[patent_title] => Antisense nucleic acid for inhibiting biosynthesis of chondroitin sulfate
[patent_app_type] => utility
[patent_app_number] => 16/498102
[patent_app_country] => US
[patent_app_date] => 2018-02-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 19185
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498102
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/498102 | Antisense nucleic acid for inhibiting biosynthesis of chondroitin sulfate | Feb 19, 2018 | Issued |
Array
(
[id] => 18133939
[patent_doc_number] => 11559588
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-24
[patent_title] => Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
[patent_app_type] => utility
[patent_app_number] => 16/487689
[patent_app_country] => US
[patent_app_date] => 2018-02-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 7
[patent_no_of_words] => 70846
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16487689
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/487689 | Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders | Feb 19, 2018 | Issued |
Array
(
[id] => 15711591
[patent_doc_number] => 20200102561
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-02
[patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
[patent_app_type] => utility
[patent_app_number] => 16/484046
[patent_app_country] => US
[patent_app_date] => 2018-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 109923
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16484046
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/484046 | Compositions and methods for the treatment of hemoglobinopathies | Feb 4, 2018 | Issued |
Array
(
[id] => 15396243
[patent_doc_number] => 10538768
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-01-21
[patent_title] => Modified TGF-beta oligonucleotides
[patent_app_type] => utility
[patent_app_number] => 15/882221
[patent_app_country] => US
[patent_app_date] => 2018-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 67
[patent_figures_cnt] => 67
[patent_no_of_words] => 15884
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15882221
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/882221 | Modified TGF-beta oligonucleotides | Jan 28, 2018 | Issued |
Array
(
[id] => 14261739
[patent_doc_number] => 10280422
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-05-07
[patent_title] => MiR-92 inhibitors and uses thereof
[patent_app_type] => utility
[patent_app_number] => 15/878176
[patent_app_country] => US
[patent_app_date] => 2018-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 24
[patent_no_of_words] => 20351
[patent_no_of_claims] => 42
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15878176
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/878176 | MiR-92 inhibitors and uses thereof | Jan 22, 2018 | Issued |
| 15/877255 | SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE | Jan 21, 2018 | Abandoned |
Array
(
[id] => 12770671
[patent_doc_number] => 20180148725
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-31
[patent_title] => UNA OLIGOMERS AND COMPOSITIONS FOR TREATING AMYLOIDOSIS
[patent_app_type] => utility
[patent_app_number] => 15/876127
[patent_app_country] => US
[patent_app_date] => 2018-01-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9866
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 84
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15876127
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/876127 | UNA oligomers and compositions for treating amyloidosis | Jan 19, 2018 | Issued |